Indole Analog Modulators for Bromodomain Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders and inflammatory diseases associated with NF-kB and p53 activity, such as cancer and multiple sclerosis, lack effective methods to modulate gene transcription and promote neural repair and oligodendrocyte differentiation.
Innovation Solution
Development of compounds that inhibit the acetyl-lysine binding activity of bromodomain-containing transcriptional co-activators, thereby attenuating gene transcriptional activity and promoting lineage progression of oligodendrocyte progenitors, which can be used to treat neurodegenerative autoimmune diseases and demyelinating disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bromodomain-containing transcriptional co-activators are inhibited, then gene transcription is attenuated and oligodendrocyte differentiation is promoted, but existing treatments lack effectiveness for neurological disorders
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (indole analogs with defined substituents R1-R6) that modulate bromodomain activity to different degrees. By varying chemical parameters such as substituent types and positions, the compounds achieve differentiated transcriptional attenuation effects, enabling effective treatment of neurological disorders while maintaining adaptability across various disease contexts
Solution Approach 2:
The patent segments the transcriptional regulation process by targeting specific bromodomain-containing co-activators (such as CBP and p300) individually. The compounds selectively inhibit acetyl-lysine binding to specific bromodomains, allowing precise control over gene transcription pathways involved in oligodendrocyte differentiation, thereby improving treatment reliability for specific neurological conditions
2Ease of operation
If acetyl-lysine binding activity is inhibited, then neural repair is promoted, but current methods lack specific mechanisms to modulate gene transcription
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that mediate between the bromodomain-containing transcriptional co-activators and acetyl-lysine. These compounds bind to the bromodomain pocket, blocking acetyl-lysine interaction and thereby attenuating gene transcription. This intermediary mechanism simplifies the approach to promoting neural repair by providing a direct chemical tool to modulate transcription without complex cellular manipulation
Solution Approach 2:
The patent replaces complex mechanical or cellular-based transcription modulation systems with small molecule chemical compounds. Instead of using gene therapy vectors, viral transduction, or complex protein-protein interaction manipulations, the invention uses orally administrable small molecules that directly bind to bromodomains, significantly simplifying the mechanism while maintaining effectiveness in promoting oligodendrocyte differentiation and neural repair
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively modulate gene transcription, promoting neural repair and myelination, and can be used to treat a range of diseases including multiple sclerosis, cancer, and inflammatory disorders by inhibiting the activity of bromodomain-containing proteins, thereby enhancing treatment outcomes.
Implementation Method 1
Bromodomain/acetyl-lysine binding is important for CBP acetyltransferase activity on biological targets, and for the recruitment of transcriptional proteins and enzymes affecting histone acetylation during gene activation
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3~3B
AI summary
This disclosure relates generally to compounds and compositions comprising one or more indole analogs. These compounds are useful for treating diseases associated with NF-kB and p53 activity, such as cancer and inflammatory diseases.